NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

So it is possible that there are a good number of patients in the trial that hale from the treatment arm who actually never even progressed. And data like that would also be very convincing, I'd think, in indicating real or true efficacy (if not statistical efficacy) of DCVax-L.

Sentiment,
I believe that Linda Liau confirms what you think in this article:

“The survival rate is quite remarkable compared to what would be expected for glioblastoma,” said lead author Dr. Linda Liau, professor of neurosurgery at the David Geffen School of Medicine at UCLA and a member of the UCLA Jonsson Comprehensive Cancer Center. “The 20 to 30 percent of long-term survivors in immunotherapy clinical trials are the people in whom we think there may be a particularly strong immune response against their cancer that is protecting them from getting tumor reoccurrence.”


http://newsroom.ucla.edu/releases/personalized-vaccine-increase-long-term-survival-glioblastoma